SIM
XENE icon

Spark Investment Management’s Xenon Pharmaceuticals XENE Stock Holding History

Spark Investment Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-26,100
Closed -$240K – 751
2018
Q2 		$240K Buy
26,100
+13,400
+106% +$83.3K 0.01% 526
2018
Q1 		$62K Buy
+12,700
New +$46.9K ﹤0.01% 574
2015
Q3 		– Sell
-10,300
Closed -$118K – 755
2015
Q2 		$118K Sell
10,300
-996
-9% -$13.8K 0.02% 585
2015
Q1 		$188K Buy
+11,296
New +$209K 0.03% 557

Other funds holding XENE

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Spark Investment Management's XENE Position: Q3 2018 in Review

Spark Investment Management sold out of Xenon Pharmaceuticals (XENE) in Q3 2018, closing a stake of 26,100 shares — an estimated $240K sold.

Spark Investment Management first reported a position in XENE in Q1 2015 and held it in 4 quarters. The position peaked at $240K in Q2 2018. 59 funds tracked by Wall St. Rank hold XENE as of Q3 2018.

  • Spark Investment Management reported no remaining Xenon Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Spark Investment Management sold 26,100 Xenon Pharmaceuticals shares in Q3 2018, an estimated $240K.
  • Spark Investment Management first reported a position in Xenon Pharmaceuticals in Q1 2015 and held it in 4 quarters.
  • Spark Investment Management's Xenon Pharmaceuticals position peaked at $240K in Q2 2018.
  • 59 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2018.

Based on Spark Investment Management's 13F filing for Q3 2018, filed 13 Nov 2018.